1. Home
  2. SWX vs TGTX Comparison

SWX vs TGTX Comparison

Compare SWX & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Southwest Gas Holdings Inc. (DE)

SWX

Southwest Gas Holdings Inc. (DE)

HOLD

Current Price

$80.51

Market Cap

5.6B

Sector

Utilities

ML Signal

HOLD

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

HOLD

Current Price

$30.95

Market Cap

5.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SWX
TGTX
Founded
1931
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.6B
5.5B
IPO Year
N/A
1995

Fundamental Metrics

Financial Performance
Metric
SWX
TGTX
Price
$80.51
$30.95
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
4
Target Price
$84.50
$54.75
AVG Volume (30 Days)
445.5K
1.6M
Earning Date
11-05-2025
11-03-2025
Dividend Yield
3.08%
N/A
EPS Growth
157.10
N/A
EPS
6.42
2.78
Revenue
$4,649,933,000.00
$531,898,000.00
Revenue This Year
N/A
$87.88
Revenue Next Year
N/A
$48.75
P/E Ratio
$24.45
$11.16
Revenue Growth
41.35
100.88
52 Week Low
$64.69
$25.28
52 Week High
$83.23
$46.48

Technical Indicators

Market Signals
Indicator
SWX
TGTX
Relative Strength Index (RSI) 49.28 46.68
Support Level $79.27 $30.40
Resistance Level $83.23 $32.30
Average True Range (ATR) 1.72 1.13
MACD 0.07 -0.00
Stochastic Oscillator 41.88 51.75

Price Performance

Historical Comparison
SWX
TGTX

About SWX Southwest Gas Holdings Inc. (DE)

Southwest Gas Holdings Inc is a utility company engaged in the purchasing, distributing, and transporting of natural gas in the American Southwest. The company segments its activities into natural gas distribution and Utility Infrastructure Services units. The first of these encompasses the company's core natural gas business as distributors in the states of Arizona and Nevada. The natural gas distribution division is responsible for roughly half of Southwest Gas' total revenue through the sale of natural gas to mainly residential and small commercial customers. The Utility Infrastructure Services segment generates the other half of the company's total revenue from the underground piping contractor services that its subsidiary, Centuri Construction Group, provides.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.

Share on Social Networks: